Avidity Partners Management LP — Quarter-over-Quarter 13F Allocation Shifts Q1 2026
In Q1 2026, Avidity Partners Management LP initiated 25 new positions, increased allocation to 9 existing positions, trimmed 9 positions, and exited 18 positions entirely. The fund's 13F equity book grew from $0.35B to $0.44B (+27.5% QoQ) . All deltas are sourced from sequential SEC Form 13F-HR filings; share-count changes reflect explicit trading activity, while weight changes can also include price movement. This page lists every position change reported — the portfolio overview shows a summary of the top shifts.
Net Portfolio Value Change
- $0.35BPrior quarter
- $0.44BCurrent quarter
- + $0.10BNet delta
- +27.5%% change
New Position Initiations Q1 2026
Securities disclosed for the first time in Q1 2026 that were not present in the prior 13F-HR filing.
Largest Allocation Increases Q1 2026
Largest portfolio-weight increases in existing positions. Share-count delta is shown separately so price-only re-weighting can be distinguished from active adds.
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| PALVELLA THERAPEUTICS INC NE | PVLA | +1.45% | +262.69% | History → |
| KARYOPHARM THERAPEUTICS INC | KPTI | +0.59% | +244.62% | Holders → |
| ENLIVEN THERAPEUTICS INC | ELVN | +3.11% | +185.10% | History → |
| PERSPECTIVE THERAPEUTICS INC | CATX | +2.79% | +88.43% | History → |
| REPLIGEN CORP | RGEN | +-0.29% | +54.67% | History → |
| CORCEPT THERAPEUTICS INC | CORT | +0.09% | +36.36% | Holders → |
| ENCOMPASS HEALTH CORP | EHC | +-0.02% | +32.91% | Holders → |
| PHATHOM PHARMACEUTICALS INC | PHAT | +-0.35% | +21.02% | Holders → |
| ORUKA THERAPEUTICS INC | ORKA | +6.00% | +15.14% | History → |
Largest Allocation Reductions Q1 2026
Largest portfolio-weight decreases in existing positions (positions kept open at a lower allocation).
| Company | Ticker | Δ Weight | Δ Shares | History |
|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC. | ACAD | -0.76% | -87.87% | Holders → |
| IMMUNIC INC | IMUX | 0.74% | -85.74% | Holders → |
| TEVA PHARMACEUTICAL INDUSTRIES LTD. - ADR | TEVA | -2.17% | -52.07% | Holders → |
| ICON PLC (ICLR) | ICLR | -1.31% | -51.66% | Holders → |
| BOSTON SCIENTIFIC CORP | BSX | -2.37% | -47.60% | Holders → |
| GENMAB A/S | GMAB | -0.52% | -45.65% | Holders → |
| NATERA | NTRA | -0.36% | -23.73% | Holders → |
| CONTEXT THERAPEUTICS INC | CNTX | 0.34% | -9.20% | History → |
| MEDTRONIC PLC | MDT | -1.15% | -7.06% | History → |
Exited Positions Q1 2026
Positions present in the prior 13F-HR filing that no longer appear in Q1 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CG ONCOLOGY INC | CGON | 17.64% |
| ALNYLAM PHARMACEUTICALS, INC. | ALNY | 2.41% |
| MCKESSON CORP | MCK | 2.25% |
| AGILENT TECHNOLOGIES, INC. (A) | A | 1.63% |
| PFIZER INC | PFE | 1.46% |
| CENTENE CORP | CNC | 1.42% |
| KENVUE, INC. | KVUE | 1.16% |
| DANAHER CORP DEL | DHR | 1.12% |
| THERMO FISHER SCIENTIFIC INC | TMO | 1.12% |
| NOVO-NORDISK A S | NVO | 0.99% |
| THE CIGNA GROUP | CI | 0.92% |
| CENCORA INC | COR | 0.92% |
| INSMED INCORPORATED | INSM | 0.89% |
| WATERS CORP | WAT | 0.89% |
| ACADIA HEALTHCARE COMPANY IN | ACHC | 0.69% |
| INTEGER HLDGS CORP | ITGR | 0.67% |
| HEALTHEQUITY INC | HQY | 0.45% |
| IQVIA HLDGS INC | IQV | 0.29% |
Methodology & FAQ
How Avidity Partners Management LP Quarterly Changes Are Computed
Each row above is computed by joining the most recent 13F-HR filing for Avidity Partners Management LP against the immediately preceding quarterly filing for the same fund. Portfolio weights are normalized to exclude listed options for comparability. A complete description of the methodology — including how confidential treatment filings are handled and why share count rather than weight is the cleaner trading signal — is documented in the Methodology.
Which positions did Avidity Partners Management LP initiate in Q1 2026?
Avidity Partners Management LP established 25 new positions in Q1 2026: AKTIS ONCOLOGY, INC. (AKTS, 1.99%), VIR BIOTECHNOLOGY INC (VIR, 1.43%), DEXCOM INC (DXCM, 1.35%), HUMANA INC (HUM, 1.34%), TEMPUS AI INC (TEM, 0.82%), TENAX THERAPEUTICS INC (TENX, 0.79%), SATELLOS BIOSCIENCE INC (MSLE, 0.70%), GILEAD SCIENCES INC (GILD, 0.59%), STRUCTURE THERAPEUTICS INC. (GPCR, 0.45%), CORVUS PHARMACEUTICALS INC (CRVS, 0.40%), INSULET CORP (PODD, 0.39%), CHARLES RIV LABS INTL INC (CRL, 0.38%), HIMS & HERS HEALTH INC (HIMS, 0.31%), PELOTON INTERACTIVE INC (PTON, 0.25%), INTELLIA THERAPEUTICS INC (NTLA, 0.23%), ODDITY TECH LTD (ODD, 0.23%), ANTERIS TECHNOLOGIES GLOBAL CO (AVR, 0.21%), ABBOTT LABS (ABT, 0.21%), MOONLAKE IMMUNOTHERAPEUTICS (MLTX, 0.19%), BRIDGEBIO PHARMA INC (BBIO, 0.16%), ARBUTUS BIOPHARMA CORP (ABUS, 0.12%), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT, 0.08%), LEGEND BIOTECH CORP (LEGN, 0.08%), SAVARA INC (SVRA, 0.06%), TREVI THERAPEUTICS INC (TRVI, 0.02%).
Which existing positions saw the largest allocation increases for Avidity Partners Management LP in Q1 2026?
The largest portfolio-weight increases in existing positions were: PALVELLA THERAPEUTICS INC NE (PVLA, +1.45% weight, +262.69% shares), KARYOPHARM THERAPEUTICS INC (KPTI, +0.59% weight, +244.62% shares), ENLIVEN THERAPEUTICS INC (ELVN, +3.11% weight, +185.10% shares), PERSPECTIVE THERAPEUTICS INC (CATX, +2.79% weight, +88.43% shares), REPLIGEN CORP (RGEN, +-0.29% weight, +54.67% shares), CORCEPT THERAPEUTICS INC (CORT, +0.09% weight, +36.36% shares), ENCOMPASS HEALTH CORP (EHC, +-0.02% weight, +32.91% shares), PHATHOM PHARMACEUTICALS INC (PHAT, +-0.35% weight, +21.02% shares), ORUKA THERAPEUTICS INC (ORKA, +6.00% weight, +15.14% shares).
Which positions did Avidity Partners Management LP fully exit in Q1 2026?
Avidity Partners Management LP fully exited 18 positions in Q1 2026: CG ONCOLOGY INC (CGON, last-reported weight 17.64%), ALNYLAM PHARMACEUTICALS, INC. (ALNY, last-reported weight 2.41%), MCKESSON CORP (MCK, last-reported weight 2.25%), AGILENT TECHNOLOGIES, INC. (A) (A, last-reported weight 1.63%), PFIZER INC (PFE, last-reported weight 1.46%), CENTENE CORP (CNC, last-reported weight 1.42%), KENVUE, INC. (KVUE, last-reported weight 1.16%), DANAHER CORP DEL (DHR, last-reported weight 1.12%), THERMO FISHER SCIENTIFIC INC (TMO, last-reported weight 1.12%), NOVO-NORDISK A S (NVO, last-reported weight 0.99%), THE CIGNA GROUP (CI, last-reported weight 0.92%), CENCORA INC (COR, last-reported weight 0.92%), INSMED INCORPORATED (INSM, last-reported weight 0.89%), WATERS CORP (WAT, last-reported weight 0.89%), ACADIA HEALTHCARE COMPANY IN (ACHC, last-reported weight 0.69%), INTEGER HLDGS CORP (ITGR, last-reported weight 0.67%), HEALTHEQUITY INC (HQY, last-reported weight 0.45%), IQVIA HLDGS INC (IQV, last-reported weight 0.29%).
Which existing positions saw the largest allocation reductions for Avidity Partners Management LP in Q1 2026?
The largest portfolio-weight reductions in positions kept open were: ACADIA PHARMACEUTICALS INC. (ACAD, -0.76% weight, -87.87% shares), IMMUNIC INC (IMUX, 0.74% weight, -85.74% shares), TEVA PHARMACEUTICAL INDUSTRIES LTD. - ADR (TEVA, -2.17% weight, -52.07% shares), ICON PLC (ICLR) (ICLR, -1.31% weight, -51.66% shares), BOSTON SCIENTIFIC CORP (BSX, -2.37% weight, -47.60% shares), GENMAB A/S (GMAB, -0.52% weight, -45.65% shares), NATERA (NTRA, -0.36% weight, -23.73% shares), CONTEXT THERAPEUTICS INC (CNTX, 0.34% weight, -9.20% shares), MEDTRONIC PLC (MDT, -1.15% weight, -7.06% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity.